Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 5/2007

01-05-2007 | Article

Genetic risk factors for diabetic nephropathy on chromosomes 6p and 7q identified by the set-association approach

Authors: K. Kaňková, A. Stejskalová, L. Pácal, S. Tschoplová, M. Hertlová, D. Krusová, L. Izakovičová-Hollá, M. Beránek, A. Vašků, S. Barral, J. Ott

Published in: Diabetologia | Issue 5/2007

Login to get access

Abstract

Aims/hypothesis

In the present study we investigated potential associations of a set of 45 single nucleotide polymorphisms (SNP) in 20 candidate genes on eight chromosomes with diabetic nephropathy (DN) in type 2 diabetes mellitus. We aimed to compare two methodological approaches suitable for analysing susceptibility to complex traits: single- and multi-locus analyses.

Materials and methods

The study comprised a total of 647 subjects in one of three groups: diabetes with or without DN, or no diabetes. Genotypes were detected by PCR-based methodology (PCR only, PCR plus RFLP, or allele-specific PCR). Haplotypes were inferred in silico. Set association (tested using SUMSTAT software) was used for multilocus analysis.

Results

After correction for multiple comparisons, only one SNP, in the gene encoding the receptor of advanced glycation end products, AGER 2184A/G (gene symbol formerly known as RAGE) showed a significant association with DN (p = 0.0006) in single-locus analysis. In multi-locus analysis, six SNPs exhibited a significant association with DN: four SNPs on chromosome 6p (AGER 2184A/G, LTA 252A/G, EDN1 8002G/A and AGER -429T/C) and two SNPs on chromosome 7q (NOS3 774C/T and NOS3 E298D), omnibus p = 0.033. Haplotype analysis revealed significant differences between DN and control groups in haplotype frequencies on chromosome 6 (p = 0.0002); however, there were no significant difference in the frequencies of the NOS3 haplotypes on chromosome 7. Logistic regression analysis identified SNPs AGER 2184A/G and NOS3 774C/T, together with diabetes duration and HbA1c, as significant predictors of DN. Testing for interactions between SNPs on chromosomes 6 and 7 did not provide significant evidence for epistatic interaction.

Conclusions/interpretation

Using the set-association approach we identified significant associations of several SNPs on chromosomes 6 and 7 with DN. The single- and multi-locus analyses represent complementary methods.
Appendix
Available only for authorised users
Literature
1.
Wolf G (2004) New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 34:785–796PubMedCrossRef
2.
Jacobsen PK (2005) Preventing end stage renal disease in diabetic patients-genetic aspect (part I). J Renin Angiotensin Aldosterone Syst 6:1–14PubMed
3.
Boright AP, Paterson AD, Mirea L et al (2005) Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes: the DCCT/EDIC Genetics Study. Diabetes 54:1238–1244PubMedCrossRef
4.
Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR (1985) The changing natural history of nephropathy in type I diabetes. Am J Med 78:785–794PubMedCrossRef
5.
The Diabetes Control and Complications Trial Research Group (1997) Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes 46:1829–1839CrossRef
6.
Borch-Johnsen K, Norgaard K, Hommel E et al (1992) Is diabetic nephropathy an inherited complication? Kidney Int 41:719–722PubMed
7.
Canani LH, Gerchman F, Gross JL (1999) Familial clustering of diabetic nephropathy in Brazilian type 2 diabetic patients. Diabetes 48:909–913PubMedCrossRef
8.
Faronato PP, Maioli M, Tonolo G et al (1997) Clustering of albumin excretion rate abnormalities in Caucasian patients with NIDDM. The Italian NIDDM Nephropathy Study Group. Diabetologia 40:816–823PubMedCrossRef
9.
Quinn M, Angelico MC, Warram JH, Krolewski AS (1996) Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39:940–945PubMed
10.
Seaquist ER, Goetz FC, Rich S, Barbosa J (1989) Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320:1161–1165PubMedCrossRef
11.
Freedman BI, Tuttle AB, Spray BJ (1995) Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus. Am J Kidney Dis 25:710–713PubMed
12.
Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC (1990) Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 33:438–443PubMedCrossRef
13.
Harjutsalo V, Katoh S, Sarti C, Tajima N, Tuomilehto J (2004) Population-based assessment of familial clustering of diabetic nephropathy in type 1 diabetes. Diabetes 53:2449–2454PubMedCrossRef
14.
Fogarty DG, Hanna LS, Wantman M, Warram JH, Krolewski AS, Rich SS (2000) Segregation analysis of urinary albumin excretion in families with type 2 diabetes. Diabetes 49:1057–1063PubMedCrossRef
15.
Imperatore G, Knowler WC, Pettitt DJ, Kobes S, Bennett PH, Hanson RL (2000) Segregation analysis of diabetic nephropathy in Pima Indians. Diabetes 49:1049–1056PubMedCrossRef
16.
Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC (1998) Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes 47:821–830PubMedCrossRef
17.
Imperatore G, Knowler WC, Nelson RG, Hanson RL (2001) Genetics of diabetic nephropathy in the Pima Indians. Curr Diab Rep 1:275–281PubMed
18.
Moczulski DK, Rogus JJ, Antonellis A, Warram JH, Krolewski AS (1998) Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q: results of novel discordant sib-pair analysis. Diabetes 47:1164–1169PubMedCrossRef
19.
Vardarli I, Baier LJ, Hanson RL et al (2002) Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3–23. Kidney Int 62:2176–2183PubMedCrossRef
20.
Liu Y, Freedman BI (2005) Genetics of progressive renal failure in diabetic kidney disease. Kidney Int Suppl Dec 99:S94–S97CrossRef
21.
Hoh J, Ott J (2003) Mathematical multi-locus approaches to localizing complex human trait genes. Nat Rev Genet 4:701–709PubMedCrossRef
22.
Heidema AG, Boer JM, Nagelkerke N, Mariman EC, van der A DL, Feskens EJ (2006) The challenge for genetic epidemiologists: how to analyze large numbers of SNPs in relation to complex diseases. BMC Genet 7:23PubMedCrossRef
23.
Hoh J, Wille A, Ott J (2001) Trimming, weighting, and grouping SNPs in human case-control association studies. Genome Res 11:2115–2119PubMedCrossRef
24.
Ding K, Zhou K, He F, Shen Y (2003) LDA-a java-based linkage disequilibrium analyzer. Bioinformatics 19:2147–2148PubMedCrossRef
25.
Abecasis GR, Cookson WO (2000) GOLD-graphical overview of linkage disequilibrium. Bioinformatics 16:182–183PubMedCrossRef
26.
Devlin B, Risch N (1995) A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 29:311–322PubMedCrossRef
27.
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc [Ser B] 57:289–300
28.
Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978–989PubMedCrossRef
29.
Kankova K, Stejskalova A, Hertlova M, Znojil V (2005) Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in type 2 diabetes mellitus. Nephrol Dial Transplant 20:1093–1102PubMedCrossRef
30.
Yamamoto Y, Doi T, Kato I et al (2005) Receptor for advanced glycation end products is a promising target of diabetic nephropathy. Ann N Y Acad Sci 1043:562–566PubMedCrossRef
31.
Ozaki K, Ohnishi Y, Iida A et al (2002) Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 32:650–654PubMedCrossRef
32.
Messer G, Spengler U, Jung MC et al (1991) Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 173:209–219PubMedCrossRef
33.
Abraham LJ, French MA, Dawkins RL (1993) Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clin Exp Immunol 92:14–18PubMedCrossRef
34.
Knight JC, Keating BJ, Rockett KA, Kwiatkowski DP (2003) In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading. Nat Genet 33:469–475PubMedCrossRef
35.
Navarro JF, Mora C, Maca M, Garca J (2003) Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am J Kidney Dis 42:53–61PubMedCrossRef
36.
Moriwaki Y, Yamamoto T, Shibutani Y et al (2003) Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 52:605–608PubMedCrossRef
37.
Kalantarinia K, Awad AS, Siragy HM (2003) Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int 64:1208–1213PubMedCrossRef
38.
Mukherjee TK, Mukhopadhyay S, Hoidal JR (2005) The role of reactive oxygen species in TNFalpha-dependent expression of the receptor for advanced glycation end products in human umbilical vein endothelial cells. Biochim Biophys Acta 1744:213–223PubMedCrossRef
39.
40.
Komers R, Anderson S (2003) Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol 284:F1121–F1137PubMed
41.
Zanchi A, Moczulski DK, Hanna LS, Wantman M, Warram JH, Krolewski AS (2000) Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 57:405–413PubMedCrossRef
42.
Ksiazek P, Wojewoda P, Muc K, Buraczynska M (2003) Endothelial nitric oxide synthase gene intron 4 polymorphism in type 2 diabetes mellitus. Mol Diagn 7:119–123PubMedCrossRef
43.
Asakimori Y, Yorioka N, Taniguchi Y et al (2002) T(−786)→C polymorphism of the endothelial nitric oxide synthase gene influences the progression of renal disease. Nephron 91:747–751PubMedCrossRef
44.
Noiri E, Satoh H, Taguchi J et al (2002) Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension 40:535–540PubMedCrossRef
45.
Rippin JD, Patel A, Belyaev ND, Gill GV, Barnett AH, Bain SC (2003) Nitric oxide synthase gene polymorphisms and diabetic nephropathy. Diabetologia 46:426–428PubMed
46.
Kohan DE (1997) Endothelins in the normal and diseased kidney. Am J Kidney Dis 29:2–26PubMed
47.
Bruzzi I, Remuzzi G, Benigni A (1997) Endothelin: a mediator of renal disease progression. J Nephrol 10:179–183PubMed
48.
Jandeleit-Dahm K, Allen TJ, Youssef S, Gilbert RE, Cooper ME (2000) Is there a role for endothelin antagonists in diabetic renal disease? Diabetes Obes Metab 2:15–24PubMedCrossRef
49.
Freedman BI, Yu H, Anderson PJ, Roh BH, Rich SS, Bowden DW (2000) Genetic analysis of nitric oxide and endothelin in end-stage renal disease. Nephrol Dial Transplant 15:1794–1800PubMedCrossRef
50.
Pinto-Sietsma SJ, Herrmann SM, Schmidt-Petersen K et al (2003) Role of the endothelin-1 gene locus for renal impairment in the general nondiabetic population. J Am Soc Nephrol 14:2596–2602PubMedCrossRef
Metadata
Title
Genetic risk factors for diabetic nephropathy on chromosomes 6p and 7q identified by the set-association approach
Authors
K. Kaňková
A. Stejskalová
L. Pácal
S. Tschoplová
M. Hertlová
D. Krusová
L. Izakovičová-Hollá
M. Beránek
A. Vašků
S. Barral
J. Ott
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 5/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-007-0606-3

Other articles of this Issue 5/2007

Diabetologia 5/2007 Go to the issue

Short Communication

Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance

Article

Global profiling of genes modified by endoplasmic reticulum stress in pancreatic beta cells reveals the early degradation of insulin mRNAs

Article

Prospective prediction of spontaneous but not recurrent autoimmune diabetes in the non-obese diabetic mouse

Article

Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men

Article

Effect of a novel non-thiazolidinedione peroxisome proliferator-activated receptor α/γ agonist on glucose uptake

Commentary

What is the scale of the future diabetes epidemic, and how certain are we about it?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits